CA2338122A1 - Antagonistes des recepteurs des monocytes macrophages - Google Patents

Antagonistes des recepteurs des monocytes macrophages Download PDF

Info

Publication number
CA2338122A1
CA2338122A1 CA002338122A CA2338122A CA2338122A1 CA 2338122 A1 CA2338122 A1 CA 2338122A1 CA 002338122 A CA002338122 A CA 002338122A CA 2338122 A CA2338122 A CA 2338122A CA 2338122 A1 CA2338122 A1 CA 2338122A1
Authority
CA
Canada
Prior art keywords
phenyl
bromo
group
phenylenediamine
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002338122A
Other languages
English (en)
Inventor
Joseph Weinstock
Robert G. Franz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2338122A1 publication Critical patent/CA2338122A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention concerne des antagonistes des récepteurs des monocytes macrophages. L'invention traite également de procédés permettant de traiter des maladies cardio-vasculaires, et consistant à administrer les composés selon l'invention qui inhibent l'accumulation des lipides dans les cellules spumeuses dérivées des macrophages.
CA002338122A 1998-07-20 1999-07-20 Antagonistes des recepteurs des monocytes macrophages Abandoned CA2338122A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9336198P 1998-07-20 1998-07-20
US60/093,361 1998-07-20
PCT/US1999/016347 WO2000003704A1 (fr) 1998-07-20 1999-07-20 Antagonistes des recepteurs des monocytes macrophages

Publications (1)

Publication Number Publication Date
CA2338122A1 true CA2338122A1 (fr) 2000-01-27

Family

ID=22238497

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002338122A Abandoned CA2338122A1 (fr) 1998-07-20 1999-07-20 Antagonistes des recepteurs des monocytes macrophages

Country Status (4)

Country Link
EP (1) EP1100484A1 (fr)
JP (1) JP2003521446A (fr)
CA (1) CA2338122A1 (fr)
WO (1) WO2000003704A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264286A1 (en) * 2000-06-16 2001-12-24 Chugai Seiyaku Kabushiki Kaisha Preventives/remedies for granuloma
AU2002254000A1 (en) * 2001-02-23 2002-09-12 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1429765A2 (fr) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibiteurs de l'histone-deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
AU2007234843B2 (en) 2006-04-07 2013-07-11 Methylgene Inc. Inhibitors of histone deacetylase

Also Published As

Publication number Publication date
WO2000003704A1 (fr) 2000-01-27
EP1100484A1 (fr) 2001-05-23
JP2003521446A (ja) 2003-07-15

Similar Documents

Publication Publication Date Title
AU730261B2 (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6458845B1 (en) Macrophage scavenger receptor antagonists
AU2012289961C1 (en) Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
WO1997046228A9 (fr) Procede de traitement de tumeurs malignes avec des analogues de thyroxine n'ayant pas d'activite hormonale importante
CA2379657A1 (fr) Inhibiteurs de transport de phosphate
CA2338122A1 (fr) Antagonistes des recepteurs des monocytes macrophages
US9738599B2 (en) Thromboxane receptor antagonists
US6255298B1 (en) Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
WO2001087294A1 (fr) Inhibiteurs du transport de phosphate
CA2339094A1 (fr) Antagonistes des recepteurs accepteurs de macrophages
US20030216449A1 (en) Phosphate transport inhibitors
WO2001098264A1 (fr) Antagonistes du recepteur de piegeurs de macrophages
CA2475454A1 (fr) Aryle-n-cyanoguanidines et procedes correspondants
JPH06502632A (ja) スルホンアミドを含む医薬組成物、新規なスルホンアミド類およびその製造方法

Legal Events

Date Code Title Description
FZDE Dead